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Abstract:  Tetherin  (BST2/CD317)  has  been  recently  recognized  as  a  potent  
interferon-induced  antiviral  molecule  that  inhibits  the  release  of  diverse  mammalian 
enveloped virus particles from infected cells. By targeting an immutable structure common 
to  all  these  viruses,  the  virion  membrane,  evasion  of  this  antiviral  mechanism  has 
necessitated  the  development  of  specific  countermeasures  that  directly  inhibit  tetherin 
activity. Here we review our current understanding of the molecular basis of tetherin’s 
mode  of  action,  the  viral  countermeasures  that  antagonize  it,  and  how  virus/tetherin 
interactions may affect viral transmission and pathogenicity. 
Keywords:  Tetherin/BST2;  restriction  of  enveloped  virus  release;  interferon;  viral 
countermeasure; Vpu 
 
1. Introduction 
The induction of the interferon response by viral infection leads to a cellular ―antiviral state‖, in 
which various signaling pathways trigger the upregulation of an array of cellular genes involved in 
host defense. Some of these genes encode proteins that directly inhibit various stages of mammalian 
virus replication. In the last decade, several examples of host-encoded antiviral proteins that potently 
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inhibit aspects of retroviral replication (so-called retroviral restriction factors) have been identified on 
the basis of the cell-type or species specificity of human immunodeficiency virus type 1 (HIV-1) 
replication.  Of  these  proteins,  members  of  the  APOBEC3  family  of  cytidine  deaminases  and 
tetherin/BST-2 are particularly notable because they target molecular features of the virus that cannot 
be varied (the chemical nature of the genome or the lipid envelope), and have thus necessitated the 
development of virus-encoded countermeasures to evade them—the accessory genes Vif and Vpu, 
respectively [1].  
Tetherin  (bone  marrow  stromal  cell  antigen  2—BST-2,  CD317)  was  discovered  as  the  factor 
responsible for the defect in virion release of HIV-1 mutants lacking the accessory gene vpu [2,3]. In 
the absence of Vpu expression, cell-free HIV-1 particles are poorly released from CD4+ T cells and 
macrophages, and mature virions accumulate on the cell surface and in vacuolar structures [4,5]. It has 
subsequently become clear that tetherin’s unique mode of action allows it to target a wide range of 
mammalian enveloped viruses, and there are now several examples of viral proteins, which, like Vpu, 
specifically counteract this antiviral factor. In this review we will focus on the recent progress and 
future  directions  in  our  understanding  of  tetherin’s  mechanism  of  action,  how  virally  encoded 
countermeasures  target  its  activity,  and  the  potential  role  of  these  interactions  in  in  vivo  viral 
transmission and pathogenesis. While most of the studies so far focus on primate lentiviruses, we will 
draw attention to general principles likely to be applicable to many other enveloped viruses. 
2. Tetherin/BST-2/CD317 
Tetherin is widely expressed in response to type I IFN, and is also constitutively expressed on 
several cell types, including mature B cells, plasma cells and plasmacytoid dendritic cells [6]. It can 
also  be  upregulated  on  myeloid  cells  and  lymphocytes  by  various  activatory  stimuli  such  as  
pro-inflammatory  cytokines,  and  in  ruminants  is  highly  expressed  in  the  endometrial  stroma 
surrounding the conceptus [7]. Prior to the discovery of its role as an antiviral effector molecule, it had 
been designated as the tumor antigen HM1.24 due to its expression on multiple myeloma cells, and has 
been of interest in this regard as a target for cancer immunotherapy [8,9]. Its expression in the bone 
marrow stroma and on B cells links it to a suspected role in B cell development [8,9], and a recent 
report suggests a role in monocyte adhesion [10]. Besides its inhibition of virus particle release, the 
only other defined physiological function of tetherin is as a ligand for the leukocyte inhibitory receptor 
ILT7 in the modulation of Toll-like receptor function [11]. 
Tetherin orthologues have been identified in the genomes of all mammals analyzed to date, and of 
those tested all possess the ability to inhibit retroviral particle release [12–14]. Curiously, the tetherin 
gene was duplicated in ruminants prior to the diversion of sheep, goats and cows  [7]. Both sheep 
orthologues  have  antiviral  activity,  although  some  differences  exist  in  their  relative  potency  [7]. 
Sequence analyses have demonstrated that tetherin, like many immunological effector molecules, has 
been under high levels of positive selection during mammalian evolution, particularly in areas of the 
protein  implicated  as  targets  for  virally  encoded  countermeasures  [12,15,16]  (see  below).  These 
analyses, while differing in their interpretation of the relative levels of positive selection between 
domains of the tetherin protein, all suggest that tetherin evolution has been shaped by the constant 
interaction with viruses and their encoded antagonists. Viruses 2011, 3                         
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Tetherin Structure, Topology and Localization 
Tetherin  is  a  small  type  II  membrane  protein  of  181  amino  acids  with  a  molecular  weight  of 
between 29 and 33 kDa depending on its glycosylation state. It has an unusual topology with both ends 
embedded in the cellular membrane by two different types of membrane anchor: a transmembrane 
domain proximal to the N-terminus and a C-terminal glycosyl-phosphatidylinositol (GPI) anchor [17] 
(Figure 1). As yet the only other protein to show a similar topology is a minor isoform of the prion 
protein PrP [18]. 
Figure  1.  Features of tetherin. A schematic representation of the structural domains of 
tetherin is shown above an alignment of the human, chimpanzee (cpz) and sooty mangabey 
(smm) amino acid sequences. Black boxes around amino acids indicate regions important 
for the antiviral function of all three tetherin proteins. Red, blue and yellow boxes indicate 
amino acids important for the recognition and/or antagonism of tetherin by HIV-1 Vpu, 
HIV-2 Env and SIV Nef, respectively. 
 
 
The two membrane anchors are connected by the extracellular domain of tetherin, comprising an 
extended coiled-coil structure; the intracellular N terminus consists of a short cytoplasmic tail. The 
extracellular  domain  of  tetherin  contains  two  N-linked  glycosylation  sites,  and  mediates 
homodimerization through disulfide linkages formed by at least one of three cysteine residues [19,20]. 
Glycosylation contributes to the correct transport and folding of the protein  [19]. Recently, partial  
X-ray crystallography structures of the extracellular domain of tetherin [21–24], have confirmed the 
presence of a parallel disulfide-linked dimeric, -helical coiled-coil. The coiled-coil contains structural 
irregularities along its length that are predicted to confer considerable flexibility [21]. In the structure 
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of the oxidized form of the human tetherin ectodomain, this N-terminal region is unresolved in the 
crystal, further suggesting conformational flexibility in this area [22]. 
Tetherin is located both at the plasma membrane and in intracellular compartments. At the plasma 
membrane, the GPI anchor embeds the C terminus of tetherin in cholesterol-rich microdomains, from 
which HIV-1 and other enveloped viruses preferentially bud  [17,25–27]. The intracellular pool of 
tetherin  is  located  predominantly  in  the  trans-Golgi  network  (TGN),  but  is  also  found  in  early 
endosomes and potentially in recycling endosomes [6,17,26,28]. Trafficking of tetherin between the 
plasma membrane and the TGN requires a tyrosine-based sorting signal in the tetherin cytoplasmic tail. 
This YxYxxϕ motif recruits clathrin adaptor complexes and is highly conserved in all known tetherin 
proteins [26,29]. This site has been shown to interact with both clathrin adaptors AP1 and AP2. The 
AP2 complex delivers tetherin to early endosomes, and the AP1 complex then mediates transport of 
tetherin between these endosomes and the TGN [26,29].  
In  polarized  epithelial  cells  tetherin  localizes  specifically  to  the  apical  surface.  Knockdown  of 
tetherin  expression  leads  to  disappearance  of  the  underlying  cortical  actin  network.  This  linkage 
between tetherin-containing microdomains and the actin cytoskeleton is mediated by BAR-RacGAP 
protein RICH2 [25]. Disruption of tetherin/RICH2 interactions leads to activation of Rac1, explaining 
the change in actin dynamics. However, what the physiological role of tetherin is in polarized cells 
remains to be determined.  
3. Antiviral Activity of Tetherin 
To  date,  tetherin  has  been  shown  to  restrict  the  release  of  retroviruses  (all  classes)  [7,30-32], 
filoviruses (Ebola virus and Marburg virus) [30,33,34], arenaviruses (Lassa virus and Machupo virus) 
[34,35],  a  paramyxovirus  (Nipah  virus)  [35],  gamma-herpesviruses  (Kaposi’s  sarcoma-associated 
herpesvirus  (KSHV))  [36,37]  and  rhabdoviruses  (vesicular  stomatitis  virus  [38]).  The  ability  of 
tetherin to target such a diverse group of viruses resides in its ability to target a feature common to 
them all: their host cell-derived lipid bilayer. This list of susceptible viruses is bound to grow, as in 
principal tetherin could target any enveloped virus that buds from cellular membrane enriched in tetherin.  
Biochemical  and  structural  evidence,  mostly  from  studies  of  HIV-1,  currently  favours  a  direct 
tethering mechanism of Virus Res.triction in which parallel tetherin dimers physically crosslink virion 
and cellular/other virion membranes. This results in the characteristic retention of mature virions in 
protease sensitive layers on the plasma membrane [2,19].  
EM studies reveal electron-dense tethers visible between the cell and the virus, or between two 
virions [2,39,40]. Furthermore, recent immune-electron microscopy studies demonstrate that tetherin is 
present between the cells and the virions, and is therefore likely to constitute the physical linkage 
responsible for attachment of nascent HIV-1 virions to the plasma membrane [19,28,40,41]. However, 
electron tomography studies will be required to provide conclusive evidence for a direct tethering 
mechanism.  Partial  protease  stripping  experiments  demonstrated  that  tetherin  is  incorporated  into  
HIV-1  virions  in  a  parallel  configuration,  although  additional  conformations  cannot  be  ruled 
out[19,40]. Interestingly, tetherin was found enriched on filamentous structures, far longer than the 
17nm estimate of a single tetherin molecule, connecting virions to the plasma membrane [40]. The Viruses 2011, 3                         
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nature of these structures and their role in tethering virus particles at the plasma membrane remain to 
be clarified.  
Studies using an artificial ―tetherin‖ have demonstrated that it is the unique topology of tetherin, 
rather  than  the  amino  acid  sequence,  that  confers  its  virus-tethering  ability  [19].  Remarkably,  a 
molecule constructed from the dimeric N-terminus of the transferrin receptor, a coiled-coil motif from 
DMPK, and a GPI anchor from uPAR was able to obstruct virus release in the same manner as the 
native molecule [19]. This also suggests that that it is unlikely that a cellular co-factor is required for 
physical particle tethering. 
Both dimerization of tetherin molecules and its GPI anchor are essential for restriction of retroviral 
particle  release  [2,19,20].  Moreover,  interactions  within  the  coiled-coil  domain  and  at  least  one 
disulfide  bond  formation  are  required  for  dimer  stability  and  HIV-1  antiviral  function  [19,20]. 
Irregularities in the extracellular coiled-coil domain are thought to confer flexibility to the molecule 
[21–23], allowing it to maintain integrity during the intense curvature of the membrane characteristic 
of virus budding. 
Following cell surface tethering, Vpu-defective HIV-1 viral particles are subject to internalization 
into endosomal compartments, probably resulting in degradation, and dominant-negative mutants of 
Rab5a can inhibit this process [2,42]. Interestingly, one study identified BCA2/rabring 7, a putative 
endocytic E3 ubiquitin ligase, as a tetherin-interaction factor capable of enhancing the internalization 
and  degradation  of  tethered  HIV-1  virions  from  the  cell  surface  [43].  An  unresolved  question  is 
whether the linkage of tetherin with the actin cytoskeleton helps to recruit tetherin to sites of virus 
budding or plays a role in re-internalization of tethered virions [17,25]. 
4. Viral Strategies to Counteract Tetherin 
The  targeting  of  the  host-derived  lipid  envelope  of  viruses  by  tetherin,  rather  than  a  specific  
virally-encoded structure, means that viruses cannot simply mutate their structural proteins to evade it. 
For an enveloped virus to successfully produce cell-free progeny virus, therefore, it must evolve a 
counter-strategy, or bud from regions of the cell membrane devoid of tetherin. 
There  are  now  several  examples  of  specific  countermeasures  that  have  evolved  in  diverse 
mammalian viruses to overcome restriction by tetherin [44]. To date, seven mammalian virus-encoded 
proteins have been reported to counteract tetherin: HIV-1 Vpu, HIV-2 Env, SIV Env, SIV Nef, SIV 
Vpu,  KSHV  K5,  and  the  Ebola  glycoprotein.  All  target  tetherin  differently  to  achieve  the  same 
purpose: the physical separation of tetherin from the site of assembling virions, usually resulting in cell 
surface downregulation. Tetherin antagonists are often (but not always) species-specific, and in the 
case  of  primate  lentiviruses  this  interplay  between  host  antiviral  factor  and  virus-encoded 
countermeasure may have had profound effects on the zoonotic transmission of these viruses and their 
adaptation to new hosts. 
4.1. Human and Simian Immunodeficiency Viruses 
Tetherin antagonism is a highly conserved attribute amongst primate lentiviruses, implying that 
evading  tetherin  is  essential  for  replication  of  these  viruses  in  vivo.  Remarkably,  the  ability  to 
counteract tetherin has arisen in three different primate lentiviral proteins (Vpu, Nef and Env), with the Viruses 2011, 3                         
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adaptation of these proteins seemingly related to the natural history of cross-species transmission and 
species-specific differences in primate tetherins (Figure 2). Amongst the six major lineages of primate 
lentiviruses, only two lineages contain Vpu in their genome, the SIVcpz/HIV-1 lineage and certain 
members of the SIVsyk lineage that include the SIVgsn sublineage (SIVmus, SIVmon, and SIVgsn), 
as well as the SIVden isolate.  
Figure  2.  Schematic representation of tetherin and its lentiviral antagonists. The black 
arrows indicate regions of interaction between tetherin and each lentiviral antagonist, as 
detailed in the text. The tetherin species specificity of each lentiviral antagonist is indicated 
in  the  light  grey  boxes.  Where  known,  the  mechanism(s)  by  which  the  antagonists 
counteract tetherin are detailed in the dark grey boxes. 
 
4.2. HIV-1 Vpu  
The prototype viral  tetherin countermeasure, HIV-1 Vpu, is a small oligomeric  transmembrane 
protein that resides in infected cells predominantly within the TGN and the endosomal system [4,45]. 
For many years the two known functions of Vpu were the degradation of CD4, and the enhancement of 
virus  release  from  certain  cell  types.  The  former  function  is  well-defined  and  entails  the  rapid 
proteasomal degradation of newly synthesized CD4 molecules to prevent their interference with the 
trafficking of viral envelope proteins (reviewed in [46]). The nature of the latter function has become 
clearer since the identification of tetherin as the cellular factor responsible for impeding the release of 
Vpu-defective HIV-1 mutants. The mechanism by which Vpu antagonizes tetherin is still matter of 
debate, and to date all experiments studying the molecular basis of this process have been conducted 
with Vpu proteins derived from Clade B laboratory isolates. It is clear that Vpu expression induces 
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tetherin accumulation in the TGN and that cytoplasmic tail truncations of Vpu that exhibit defects in 
localisation  to  the  TGN  are  impaired  in  antagonism  [47].  Moreover,  Vpu  expression  causes  a 
downregulation of cell-surface tetherin levels [3], and the total level of cellular tetherin are decreased 
in  the  presence  of  Vpu  in  most  cellular  systems  [15,48–51].  However,  whether  degradation  and 
downregulation of tetherin are absolutely required for Vpu antagonism of tetherin-mediated restriction 
is less apparent.  
4.2.1. Vpu Interaction with Tetherin 
Several studies have demonstrated that HIV-1 Vpu and human tetherin physically interact via their 
respective transmembrane domains [52–57]. This interaction is highly species-specific as single point 
mutations in the transmembane domain of tetherin render it resistant to Vpu-mediated antagonism 
[12,15]. Reciprocally, mutations in the transmembrane domain of Vpu diminish its ability to interact 
with and antagonize tetherin [54]. Interestingly mutations in both proteins’ transmembrane domains 
that abolish physical interaction lie along single faces of the respective membrane spanning helices 
[54,56]. This, and the fact that Vpu transmembrane domain mutants that are defective for tetherin 
interaction are distinct from those that contribute to Vpu’s multimerization or putative ion channel 
function [54,57], are suggestive that Vpu targets tetherin as a monomer.  
4.2.2. The Role of Tetherin Degradation in Antagonism by Vpu 
Tetherin is degraded both in cells transfected to express Vpu in trans and in cells infected with 
wild-type  HIV-1  [15,48–51].  Tetherin  levels  in  cell  lysates  can  be  restored  by  both  proteasomal 
[15,48,49,58]  and  endolysosomal  inhibitors  [50,51,53]  leading  to  debate  as  to  whether  tetherin  is 
degraded in lysozomes or by cytoplasmic proteasomes after extraction from intracellular membranes. 
Because  inhibition  of  tetherin  degradation  in  infected  cells  by  proteasomal  inhibitors  requires 
prolonged exposure that is known to deplete cytoplasmic ubiquitin, the more likely situation is that 
tetherin  is  degraded  by  an  ubiquitin-dependent  endosomal  degradation,  recently  furthered  by  the 
implication of HRS and the ESCRT pathway in tetherin turnover  [59]. Moreover data supporting 
proteasomal-dependent  degradation  of  Vpu  have  in  general  come  from  the  use  of  exogenously 
expressed  epitope-tagged  tetherin,  which  often  results  in  a  ―backing-up‖  of  immature  tetherin 
molecules in the ER and subsequent ER-associated degradation, suggesting that initial reports of the 
20S proteasome being directly involved in tetherin degradation are artifactual [60]. 
The expression of Vpu induces tetherin ubiquitination, with the human tetherin cytoplasmic tail 
possessing both lysine and serine/threonine residues that can act as ubiquitin acceptors in the presence 
of  Vpu  [37,58,61].  The  most  likely  E3-ligase  candidate  for  direct  tetherin  ubiquitination  is  the  
-transducin repeat-containing protein 2 (-TrCP) subunit of a Skp1-Cullin1-F-box ubiquitin ligase 
complex.  As  observed  with  Vpu-mediated  CD4  downregulation,  recruitment  of  -TrCP-SCF-Skp 
1-Cul1-F-box  is  required  for  tetherin  degradation.  -TrCP  1  and  2  bind  to  a  highly  conserved 
phosphorylated serine motif (DSGNES) in the Vpu cytoplasmic tail, and are linked to the rest of the 
E3 ligase complex via an F-box motif [62,63]. Although disruption of the interaction between -TrCP2 
and the cytoplasmic tail of Vpu reduces the capacity of Vpu to enhance virus release [49–51,53,55], 
there is increasing evidence to show that Vpu’s anti-tetherin mechanism does not necessarily require Viruses 2011, 3                         
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degradation of the restriction factor. For instance, mutation of both serine residues within the Vpu 
DSGNES motif preclude binding to -TrCP and prevent cell surface downregulation of tetherin, yet 
this mutant Vpu retains some ability to promote virus release [3,51]. Furthermore, while mutation of 
lysine residues in the cytoplasmic tail of human tetherin renders the protein resistant to Vpu-induced 
degradation, these proteins are still sensitive to Vpu-mediated antagonism [37,58]. Additionally, one 
study  demonstrated  that  in  infected  T-cell  lines,  tetherin  surface  expression  was  only  mildly 
downregulated despite efficient virus release [64]. 
4.2.3. Intracellular Sequestration as a Mechanism for Antagonism 
If tetherin degradation is dispensable for Vpu activity, the most likely mechanism for antagonism of 
its function is its physical compartmentalization away from budding virions at the cell surface. Many 
studies have shown that tetherin is downregulated from the cell surface in response to Vpu expression, 
leading to less incorporation into virions [19,41]. Vpu does not affect the rate of internalization of cell 
surface tetherin [51,55,60], but rather sequesters de novo synthesized or recycling tetherin away from 
the plasma membrane, probably in the TGN [55,58,65]. This sequestration is sufficient to block the 
restriction activity of tetherin, and the appropriated tetherin is presumably redirected to the lysosomal 
compartment for degradation, leading to net depletion of tetherin from the cell surface  [60]. This  
Vpu-mediated  sequestration  of  tetherin  may  also  be  ubiquitin  dependent.  Recently  serine-  and 
threonine-linked  ubiquitination  of  tetherin  has  been  implicated  in  inactivation  and  surface 
downregulation  by  Vpu  [61],  although  whether  this  is  demonstrable  at  physiological  tetherin 
expression levels is unclear. In some cases, this trapping antagonism mechanism may be augmented by 
concomitant Vpu-dependent -TrCP-dependent degradation of tetherin, suggesting that Vpu uses more 
than one mechanism to counteract tetherin restriction [55,65]. A recent study suggested that HRS, an 
ESCRT-associated factor that binds ubquitinated cargo, interacts with Vpu/tetherin complexes and was 
required for antagonism in addition to its clear role in tetherin degradation [59]. However, a potential 
confounding issue with these observations is that HRS depletion has a marked inhibitory effect on 
HIV-1 particle production irrespective of whether cells express tetherin or not. 
The  Vpu  proteins  from  SIVgsn  (greater  spot-nosed  monkey),  SIVmus  (mustached  monkey), 
SIVmon (Mona monkey) and SIVden (Dent’s Mona monkey) are capable of counteracting tetherin of 
their simian hosts [66,67]. In contrast, the Vpu from SIVcpz (chimpanzee), the immediate precursor of 
HIV-1, which shares a common ancestry with SIVgsn/mus/mon Vpu, cannot [66,67]. SIVcpz is in fact 
a recombinant virus derived from two lineages of SIV and as outlined below, tetherin antagonism has 
developed separately in two other lentiviral genes. Furthermore, the re-adaptation of HIV-1 Vpu to 
human tetherin may have had profound consequences for the spread of these viruses in humans. 
4.3. SIV Nef  
Many SIV strains do not encode a Vpu protein. Rather, the Nef protein of SIVmac (macaque), and 
also of SIVagm (African green monkey), SIVsm (sooty mangagey), SIVblu (blue monkey), and SIV 
cpz (chimpanzee), can enhance virus release from cells expressing the tetherin proteins derived from 
their simian hosts [66–69]. Nef is a myristoylated adaptor protein that localizes to the cytosolic face of 
cellular  membranes.  This  immunomodulatory  protein  is  known  to  remove  cell-surface  proteins Viruses 2011, 3                         
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involved in immune recognition, including CD4, MHC class I and II [70]. Many SIV Nef proteins also 
induce  the  cell-surface  downregulation  of  primate  tetherin  molecules  and  this  downregulation 
correlates with enhanced viral particle release [69]. However, the underlying mechanistic details of this 
process remain to be determined.  
None of the SIV Nef proteins are able to counteract human tetherin, and this specificity maps to five 
amino acids  (G/DDIWK)  in  the cytoplasmic  domain of simian tetherin that are  missing from the 
human orthologue [16,67–69], leading to speculation that prehistoric infection with viruses encoding 
Nef-like tetherin antagonists may have selected this deletion. The reinsertion of this motif into human 
tetherin is sufficient to render it sensitive to SIVmac Nef [68]. Likewise, Nef proteins from both HIV-1 
and HIV-2 are unable to antagonize human tetherin, but retain some activity against the rhesus protein 
[68,69]. 
4.4. HIV-2 and SIV envelope proteins  
The third primate lentiviral protein in which tetherin antagonism has been described is the envelope 
glycoprotein encoded by HIV-2. As with Vpu, the ability of HIV-2 Env to promote virus release from 
certain cell types was recognized long before this was attributed to the antagonism of tetherin [71]. 
HIV-2  Env  is  able  to  directly  interact  with  tetherin,  and  like  Vpu  promotes  its  cell  surface 
downregulation and sequestration in intracellular compartments, thus excluding tetherin from the site 
of virus assembly and budding [31,65,72,73]. The exact determinants of tetherin antagonism in HIV-2 
Env have yet to be deciphered, but it is clear that a highly conserved endocytic sorting motif (GYxxϕ) 
in the gp41 cytoplasmic tail is essential. This motif binds to the clathrin adaptor complex AP-2, and 
presumably  facilitates  the  re-direction  of  tetherin  molecules  away  from  the  plasma  membrane, 
sequestering them in a perinuclear compartment [31,65,72,73]. Several studies have implicated the 
ectodomain of gp41 in tetherin antagonism  [31,72,74], but which regions are important for direct 
interactions and which are needed to maintain a specific structural conformation of the Env complex is 
unclear. In this respect, proteolytic processing of the envelope into the subunits gp120 and gp41 is also 
required, as the unprocessed form (gp160) is unable to promote virus release [31,75]. Mutations in the 
ectodomain  of  human  tetherin  render  HIV-2  Env  incapable  of  counteracting  restriction  [76] 
(specifically, an alanine to aspartic acid substitution at position 100 [14]), supporting the model of an 
interaction between the ectodomains of both proteins. 
Interestingly, there are two documented cases of SIV Env proteins able to antagonise tetherin. The 
first is an Env protein from a virus originally isolated from a naturally infected tantalus monkey [76]. 
This SIVtan Env shows a similar ability to HIV-2 Env and HIV-1 Vpu to exclude tetherin from the site 
of viral budding, resulting in a reduction in surface tetherin levels [14]. The laboratory strain of SIVtan 
was first isolated from the tantalus monkey by co-culturing monkey and human lymphocytes, and the 
Nef protein from this virus does have weak activity against its host species tetherin [16]. This raises 
the possibility that this human cell type adaptation has influenced its ability to antagonise human 
tetherin, and may not be reflective of Env-mediated antagonism in the natural host. The second case of 
an  SIV  Env  tetherin  antagonist  involves  a  pathogenic  nef-deleted  SIVmac  virus  isolated  from 
experimentally infected rhesus macaques. Nef-defective mutants of SIVmac are generally attenuated, 
maintaining  a  low  level  chronic  infection  that  does  not  usually  progress  to  AIDS.  However,  on Viruses 2011, 3                         
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occasion  pathogenic  revertants  have  been  isolated.  Upon  investigation  of  the  determinants  of  re-
acquired  pathogenicity,  it  was  shown  that  the  Env  protein  had  acquired  the  ability  to  overcome 
restriction of virus release specifically by an allele of rhesus tetherin [77,78]. The exact determinants 
of tetherin antagonism in the SIV Env protein were mapped, and it is of note that they are different 
from  those  implicated  in  the  HIV-2  Env  [78].  While  both  Envs  require  the  membrane-proximal 
GYxxϕ endosomal sorting motif in the gp41 cytoplasmic tail, the remainder of the cytoplasmic tail is 
dispensable  in  HIV-2  Env  [31,72,79],  with  the  ectodomain  postulated  to  interact  with  tetherin 
[31,72,74]; for the nef-deleted SIVmac, the ectodomain of Env is dispensable and activity maps to 
several amino acid substitutions in the C-terminal cytoplasmic tail, and grafting of the tail onto a 
heterologous membrane protein (CD4) is sufficient to generate a chimeric tetherin antagonist [78]. 
Unlike HIV-2, SIVmac Env-mediated tetherin interaction and targeting is highly species-specific and 
is  determined  by  residues  flanking  the  tetherin  di-tyrosine  endocytic  sorting  motif,  which  is  also 
essential for antagonism. There is no effect of the A100D determinant in the tetherin coiled-coil. Thus, 
the acquisition of function in the SIV Env protein represents an independent and distinct parallel of the 
evolution of the tetherin antagonistic property of HIV-2 Env. 
4.5. Tetherin and HIV-1 and HIV-2 Zoonoses and Pathogenesis 
Of the four HIV-1 groups (M, N, O and P) that arose from independent zoonoses of SIVcpz, only 
Vpu proteins of HIV-1 group M and a few strains from group N appear able to efficiently counteract 
tetherin [66]. Group M has given rise to the HIV-1 pandemic, whilst group O has caused localized 
epidemics predominantly in Cameroon where it represents 1–2% of the total HIV-1 incidence. Very 
few isolates of Groups N and P have been sequenced. The relative inefficiency of HIV-1 Group O 
transmission despite maintaining the ability to cause AIDS, has led to speculation that adaptation of 
Vpu to human tetherin was an essential step in the establishment of the HIV-1 human pandemic. In the 
few sequences available for HIV-1 group N, by contrast, tetherin antagonism is variable, but CD4 
degradation (present in SIVcpz Vpu) was lost, suggesting that the pressure to adapt to human tetherin 
in Group N may have disabled this function. Analysis of the TM domains of M, N and O and SIVcpz 
Vpu  proteins  reveals  that  the  SIVcpz  and  Group  O  TMs  differ  significantly  along  their  length 
including  in  positions  known  to  be  important  of  Group  M  Vpu  function  [66].  For  SIVcpz  Vpu, 
adaptation of the TM domain is sufficient to confer targeting of human tetherin [16]. Finally, while 
Group O Vpu proteins lack tetherin antagonism, it is not known whether the virus has, like HIV-2, 
acquired this function in its envelope protein. There is one report of an HIV-1 group M virus (AD8) 
with a Vpu-like activity associated with its envelope [80], but to date this observation has not been 
confirmed in the light of the discovery of tetherin. 
It is clear that the Env protein of HIVs and SIVs has the capacity to evolve anti-tetherin activity. 
This may represent a ―reserve‖ measure in certain situations, as demonstrated by the fact that the  
HIV-2 Env and an SIVmac Env have gained this function independently and in different regions of the 
protein. Neither virus was able to enlist Nef to overcome tetherin in its host species: clearly in the  
nef-deleted  SIVmac  this  is  because  the  virus  was  engineered  to  lack  Nef;  for  HIV-2  this  was  a 
consequence of the human tetherin lacking the five amino acids that confer susceptibility to Nef. 
Likewise,  both  viruses  are  descendents  of  an  SIV  lineage  that  does  not  encode  a  Vpu  protein. Viruses 2011, 3                         
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Therefore, Env acts as a third means of counteracting tetherin and establishing infection in a new host. 
We can only speculate as to whether this has a cost for the virus. In the case of HIV-1 and SIV, 
tetherin counter-strategies are adopted by accessory proteins that play multiple roles in the modulation 
of the host environment in vivo. In contrast, for HIV-2/SIV Envs, this role is undertaken by a major 
structural  protein,  responsible  for  the  entry  of  the  virus  into  target  cells  whilst  under  pressure  to 
constantly evolve to evade attack by the humoral immune response. Furthermore, as Env appears to 
counteract  tetherin  by  chaperoning  and  sequestering  it  in  intracellular  compartments,  this  might 
decrease the levels of infectious virus produced due to a reduced availability of Env protein during 
assembly. Thus, it is possible that maintaining tetherin antagonistic ability in the Env protein has 
consequences for viral fitness. Whether this contributes to the lower virulence of HIV-2 is unknown. 
4.6. Filoviruses: Ebola GP 
Ebola virus encodes 7 genes, of which the viral glycoprotein (GP), found on the surface of virions 
and  responsible  for  mediating  target  cell  entry,  is  able  to  antagonize  tetherin  [33].  Through  a 
mechanism that is currently unclear, Ebola virus GP appears to counteract tetherin without removing it 
from  the  cell  surface  [81].  Furthermore,  the  Ebola  GP  does  not  seem  to  require  specific  tetherin 
sequences for its activity, as it is able to counteract an artificial tetherin, and to date is the only viral 
tetherin antagonist able to do so [81]. Supporting a less specific mode of action, Ebola GP is also able 
to antagonize mouse tetherin, a protein possessing only 36% sequence homology to primate tetherins 
[33].  Thus,  Ebola  GP  seems  to  have  a  broader  activity  than  the  lentiviral  antagonists,  perhaps 
reflecting the breadth of mammalian host species infected by the Ebola virus.  
4.7. Herpes Viruses: K5 KSHV 
Before its identification as an antiviral factor, tetherin had been identified in a proteomic screen for 
novel targets of K5, a membrane-bound RING-CH (MARCH) domain E3 ubiquitin ligase encoded by 
the Kaposi's sarcoma-associated herpesvirus (KSHV; also known as human herpesvirus 8 (HHV8)) 
[82].  K5  is  an  immuno-modulator  that  mediates  the  downregulation  of  a  variety  of  cell-surface 
molecules involved in the immune recognition of virally infected cells, such as MHC class I proteins, 
adhesion molecules and NK receptor ligands [83]. K5 exerts its effects by directly ubiquitinating the 
cytoplasmic  tails  of  its  target  proteins  to  induce  ESCRT-dependent  degradation.  K5  induces  a  
species-specific downregulation of human tetherin from the cell surface followed by its lysosomal 
degradation, and in its absence the release of progeny KSHV virions from tetherin positive cells is 
inhibited [36,37]. This K5-mediated tetherin degradation is ESCRT-dependent and requires the direct 
ubiquitination of a lysine residue at position 18 in the cytoplasmic tail of tetherin [36,37], and unlike 
Vpu this ubiquitin-coupled degradation is essential for K5 to counteract tetherin function. MARCH 
ligase homologues are found in several γ2 herpesviruses and poxviruses although whether tetherin 
antagonism is a conserved function is unknown. Herpesviruses have a complex envelopment strategy 
involving  budding  and  fusion  of  immature  viruses  through  the  nuclear  membrane,  followed  by 
ESCRT-dependent budding through internal membranes. The implication of tetherin in restriction of 
KSHV particle release suggests that all herpesviruses may be susceptible to its antiviral activity. Given Viruses 2011, 3                         
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the proportion of the genomes of these viruses accounted for by immune evasion genes, it is likely that 
many other herpesvirus-encoded proteins with anti-tetherin functions await discovery. 
5. Tetherin and Cell-to-Cell Transmission 
HIV-1 and other human retroviruses spread within a host both through cell-free virus dissemination 
and  through  direct  cell-to-cell  contact  via  the  virological  synapse  (VS)  [84,85].  Formation  of  the 
virological synapse between infected and target cells is an active process, analogous to the formation 
of the immunological synapse, involving polarized cytoskeletal remodeling and enrichment of viral 
proteins  and  cellular  receptors  at  the  site  of  cell  contact.  Viral  production  in  the  infected  cell  is 
polarized towards the site of contact with the target cell, and several recent studies have confirmed the 
presence of tetherin at the VS [86–88]. Early studies of Vpu-defective HIV-1 replication in T cell lines 
suggested that while virus production was inhibited, viral spread in the culture was not [4,89–92]. 
Moreover, selection for HIV-1 variants that spread more efficiently by cell-to-cell spread results in 
inactivating mutations in Vpu  [93]. Therefore re-evaluation of VS-transfer has become of interest 
recently with respect to the influence of tetherin on this process. However, so far opposing results have 
been described. 
Tetherin-mediated retention of mature virions on the cell surface might inhibit cell-to-cell virus 
transfer due to aggregation and reduced infectivity of the virions [87,94] or could promote cell-to-cell 
transfer by providing a concentration of immobilized, infectious virions at the focal point of virus 
production [86]. Indeed, as the recent literature supports both scenarios it is likely that the outcome is 
influenced by cell type, modulation of tetherin expression levels by interferon, and the kinetics of the 
process  itself.  For  example,  it  has  been  observed  that  in  macrophages  the  replication  of  a  virus 
expressing a Vpu severely impaired in its ability to counteract tetherin was significantly compromised 
compared  to  the  wildtype  virus,  whereas  replication  of  the  same  Vpu-defective  virus  was  not 
significantly diminished in CD4+ T cells [95]. Furthermore, despite apparently contrasting results with 
regards to the effect of tetherin on cell-to-cell virus transmission, all studies demonstrated that the 
reductions in cell-free virus production caused by tetherin were far more effective than any reduction 
seen in cell-to-cell spread [86,87,94]. The possibility emerges, therefore, that cell-to-cell spread may 
allow  the  systemic  spread  of  virions  that  would  otherwise  be  thwarted  by  tetherin,  particularly 
considering that no retrovirus beyond the lentivirus genus has been described to encode a tetherin 
antagonist.  Since  tetherin  antagonism  is  highly  conserved  this  would  imply  that,  for  primate 
lentiviruses at least, efficient replication and transfer in vivo must balance cell-free and cell-to-cell 
spread, particularly under conditions of high interferon induction (such as acute HIV-1 infection). 
Another intriguing possibility is whether tetherin plays a role in the structure of the VS itself. While 
Vpu mediates tetherin downregulation in infected T cells, in one study this effect appeared delayed 
[86], and tetherin knock-down also interfered with wild-type virus transfer. Whether this is related to 
the  situation  in  polarised  epithelial  cells,  wherein  tetherin  has  been  shown  to  interact  with  the 
underlying actin cytoskeleton via the BAR-RacGAP protein RICH2 and is concentrated at the apical 
surface of the cells, remains to be seen [25]. 
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6. Tetherin and the Wider Antiviral Immune Response 
All studies on tetherin thus far have addressed its effects on virus replication and virion production 
in vitro. However the importance of tetherin in the global immune response to viral infection has yet to 
be addressed. There are several points at which the actions of tetherin may influence other components 
of the immune response, all of which may account for the pressure to develop tetherin antagonists over 
and above its inhibitory activity on virion production. 
6.1. Antigen Presentation  
Viral particles targeted to degradative compartments by tetherin may have consequences in antigen 
presenting  cells,  such  as  macrophages  and  dendritic  cells.  For  example,  in  macrophages,  the 
localization of HIV-1 assembly is complex. Virions assemble and accumulate in deep invaginations of 
the plasma membrane, where they might be sequestered and released on contact with T cells across 
synaptic  structures  [96,97].  In  addition,  Vpu-defective  HIV-1  virus  particles  accumulate  in 
phagosomal structures derived from phagocytic events at the plasma membrane [98]. Thus it is likely 
that  tetherin-HIV  interactions  result  in  differential  subcellular  accumulation  of  newly  assembled 
virions. This raises the possibility that in antigen presenting cells, such as macrophages, which are 
targets  for  HIV-1  infection  in  vivo,  tetherin-restricted  virions  could  be  targeted  for  proteolytic 
destruction in phagosomes and viral components processed for antigen presentation. If so, tetherin-
mediated enhanced presentation of viral components to the adaptive immune system will be important 
in the generation and augmentation of an adaptive immune response. 
6.2. Enhanced Humoral Recognition of Infected Cells  
A further, more general effect of tetherin-restriction of particle release, is the ―visibility‖ that this 
may give an infected cell to adaptive humoral responses. Depending on the length of exposure to the 
extracellular milieu, the cell surface-tethered virions themselves may be targets for enhanced antibody 
deposition.  Therefore,  virions  trapped  on  the  cell  surface  (and  the  cell  itself)  may  be  subject  to 
complement-mediated destruction or direct cytotoxicity by phagocytes and natural killer cells and the 
enhanced inflammatory signals that these activities stimulate. 
6.3. Tetherin as a Ligand for Other Immune Receptors  
Recent data have suggested a role for tetherin as a regulator of the interferon response to tumor 
cells. Specifically, tetherin can act as a ligand for the leukocyte inhibitory receptor ILT7, both of which 
are expressed on plasmacytoid dendritic cells (pDCs) [11]. This interaction in cis on pDC surfaces 
inhibits signaling through Toll-like receptors 7 and 9 (TLR 7/9) to their respective ligands. Detection 
of viral nucleic acid by TLRs 7 and 9 induces an interferon response in pDCs, and these cells are 
recognised as being among the most potent producers of type I IFN during viral infection [99]. While 
the  production  of  IFN  by  pDCs  induces  the  upregulation  of  tetherin  on  cells  in  the  vicinity,  the 
engagement ILT7 by tetherin inhibits the production of IFN and inflammatory cytokines by pDCs in a 
negative feedback loop [11]. However ILT7 expression is restricted to pDCs. Does tetherin affect TLR 
function  differently  in  the  absence  of  ILT7  or  in  trans?  Lysosomal  degradation  of  viral  particles Viruses 2011, 3                         
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releases virion components that are ligands for endosomal TLRs. Tetherin restriction of viral particles 
may therefore lead to increased recognition of viral nucleic acid by TLRs 7 and 9 either in cis or trans, 
and  in  turn  upregulate  the  host  response  to  viral  infection  by  increasing  the  expression  of  IFN, 
inflammatory cytokines and molecules involved in viral immune surveillance. Furthermore tetherin 
may itself possess an intrinsic signaling capacity. In a large-scale screening study it was identified as a 
potent  inducer  of  NF-kB  [100].  It  will  be  interesting  to  see,  therefore,  what  the  inflammatory 
consequences of this may be. 
7. Concluding Remarks 
In the last few years, much understanding of tetherin structure and function has been gleaned, 
particularly with respect to its interactions with HIVs and SIVs, and has led to suggestions that it has 
acted as a powerful selective pressure on primate lentiviruses. However, the seeming simplicity of its 
mechanism underlines its potential to act as a potent generalized inhibitor of enveloped virus release. 
Furthermore, virus/tetherin interactions in vivo are likely to lead to further immune activation that may 
augment and modulate adaptive antiviral responses. The high degree of positive selection on tetherin 
during mammalian evolution, and the coding capacity that several diverse enveloped viruses have 
given to develop proteins that specifically target it, imply that tetherin is an important antiviral weapon 
in the arsenal of the innate immune response. 
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